Dassault Systèmes (ENXTPA:DSY) is in focus after its Medidata unit launched Medidata Plus, an AI layer that integrates artificial intelligence across the Medidata clinical trial platform to support an end to end AI strategy.
See our latest analysis for Dassault Systèmes.
The Medidata Plus launch and recent talk of a possible ArisGlobal acquisition come as Dassault Systèmes trades at €20.21, with a 1 month share price return of 13.44% but a 1 year total shareholder return that has declined 29.10%. This points to improving short term momentum against a weaker multi year picture.
If this AI driven clinical trial update has your attention, it can be a good moment to widen your search and review 66 profitable AI stocks that aren't just burning cash.
Dassault Systèmes has bounced in the short term, while longer term holders are still sitting on sizeable declines. Do the current earnings profile and AI ambitions leave enough upside in the valuation to justify taking that risk?
Most Popular Narrative: 12.2% Undervalued
The most followed narrative currently sees Dassault Systèmes as worth €23.02 a share, compared with the latest close at €20.21. This puts the focus squarely on its long term AI and virtual twin push.
The ongoing transition to SaaS and subscription models (83% of software revenues now recurring), combined with early and rapid commercialization of AI-powered virtual twins and companions, offers both short-term visibility and long-term margin improvement, with substantial runway for earnings and free cash flow upside.
Curious how this recurring revenue engine links to the valuation gap. The narrative leans heavily on future earnings power and a richer profit profile. The key is how much growth and what multiple that could support. The full story joins these moving parts into one valuation view.
Result: Fair Value of €23.02 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Dassault Systèmes narrative still faces real pressure from slower Medidata momentum in Life Sciences and more uneven timing of large deals, which could unsettle earnings expectations.
Find out about the key risks to this Dassault Systèmes narrative.
Next Steps
With sentiment around Dassault Systèmes still divided, it can help to move quickly and test the story against the numbers yourself. To see what investors are optimistic about, start by reviewing the 4 key rewards.
Looking for more investment ideas beyond Dassault Systèmes?
Once you have formed a view on Dassault Systèmes, do not stop there. A wider watchlist can help you spot opportunities you might otherwise overlook.
- Scan for potential mispriced opportunities by checking companies in the 257 high quality undervalued stocks.
- Prioritise resilience and sleep a little easier at night with the 310 resilient stocks with low risk scores.
- Spot earlier stage opportunities before wider attention arrives by reviewing the screener containing 525 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com